Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs

Objective: To assess the prevalence of potentially teratogenic drug utilization by pregnant women: overall and in the periconceptional period. Methods: The electronic database PubMed/Medline was searched for the following keywords: «pharmacoepidemiology», «pregnancy», «drug use», «safety», «pregnanc...

Full description

Saved in:
Bibliographic Details
Main Authors: Olga V. Reshetko, Konstantin A. Lutsevich, Irina I. Sanina
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2017-08-01
Series:Педиатрическая фармакология
Subjects:
Online Access:https://www.pedpharma.ru/jour/article/view/1513
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849395922211962880
author Olga V. Reshetko
Konstantin A. Lutsevich
Irina I. Sanina
author_facet Olga V. Reshetko
Konstantin A. Lutsevich
Irina I. Sanina
author_sort Olga V. Reshetko
collection DOAJ
description Objective: To assess the prevalence of potentially teratogenic drug utilization by pregnant women: overall and in the periconceptional period. Methods: The electronic database PubMed/Medline was searched for the following keywords: «pharmacoepidemiology», «pregnancy», «drug use», «safety», «pregnancy risk category», «fetal risk», «teratogen». The systematic analysis included 28 studies published in English from January 2006 to 23 December 2015. Results. The review shows that the study designs and the choices for data analysis and presentation of results differ largely across published studies. In the USA and Canada, measured rates of maternal use of contraindicated drugs (FDA category X) during pregnancy ranged from 2.4% to 5.3% (1.1–5.0% in the first trimester).The use of drugs with positive evidence of risk (FDA category D) ranged from 5.8% to 39.6% (2.7–6.0%). In European countries, proportions of women using drugs of risk categories X and D ranged from 1.0% to 4.9% (0.31–3.2%) and from 2.0% to 5.9% (1.6–3.7%), respectively. In developing countries, respective proportions of women ranged within 0.2–2.1% and 1.9–11.4%. In early pregnancy (the first trimester), the proportion of women taking potentially teratogenic drugs was high if compared with the second and third trimesters. The use of contraindicated drugs during pregnancy fastly decreases compared with the period before conception. Although the reduction of use of drugs with positive evidence of risk is less marked, possibly, with relation of their efficacy for the treatment of chronic conditions. On the base of analyzed studies, the reference list of potentially teratogenic drugs was formed. Conclusion. The results of published literature confirm differences in study methods that make it difficult to compare the application of potentially teratogenic drugs in pregnancy. The fundamental challenge remains an insufficiency or lack of available information on the evidence of risk to fetus cuased by the drugs that are most widely used in pregnancy.
format Article
id doaj-art-c5b79a0d899d460583e6afe50d71c007
institution Kabale University
issn 1727-5776
2500-3089
language Russian
publishDate 2017-08-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-c5b79a0d899d460583e6afe50d71c0072025-08-20T03:39:28ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892017-08-0114212714110.15690/pf.v14i2.17271485Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic DrugsOlga V. Reshetko0Konstantin A. Lutsevich1Irina I. Sanina2Saratov State Medical University named after V.I. RazumovskySaratov State Medical University named after V.I. RazumovskySaratov State Medical University named after V.I. RazumovskyObjective: To assess the prevalence of potentially teratogenic drug utilization by pregnant women: overall and in the periconceptional period. Methods: The electronic database PubMed/Medline was searched for the following keywords: «pharmacoepidemiology», «pregnancy», «drug use», «safety», «pregnancy risk category», «fetal risk», «teratogen». The systematic analysis included 28 studies published in English from January 2006 to 23 December 2015. Results. The review shows that the study designs and the choices for data analysis and presentation of results differ largely across published studies. In the USA and Canada, measured rates of maternal use of contraindicated drugs (FDA category X) during pregnancy ranged from 2.4% to 5.3% (1.1–5.0% in the first trimester).The use of drugs with positive evidence of risk (FDA category D) ranged from 5.8% to 39.6% (2.7–6.0%). In European countries, proportions of women using drugs of risk categories X and D ranged from 1.0% to 4.9% (0.31–3.2%) and from 2.0% to 5.9% (1.6–3.7%), respectively. In developing countries, respective proportions of women ranged within 0.2–2.1% and 1.9–11.4%. In early pregnancy (the first trimester), the proportion of women taking potentially teratogenic drugs was high if compared with the second and third trimesters. The use of contraindicated drugs during pregnancy fastly decreases compared with the period before conception. Although the reduction of use of drugs with positive evidence of risk is less marked, possibly, with relation of their efficacy for the treatment of chronic conditions. On the base of analyzed studies, the reference list of potentially teratogenic drugs was formed. Conclusion. The results of published literature confirm differences in study methods that make it difficult to compare the application of potentially teratogenic drugs in pregnancy. The fundamental challenge remains an insufficiency or lack of available information on the evidence of risk to fetus cuased by the drugs that are most widely used in pregnancy.https://www.pedpharma.ru/jour/article/view/1513pharmacoepidemiologypregnancydrugsteratogensafetysystematic review
spellingShingle Olga V. Reshetko
Konstantin A. Lutsevich
Irina I. Sanina
Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs
Педиатрическая фармакология
pharmacoepidemiology
pregnancy
drugs
teratogen
safety
systematic review
title Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs
title_full Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs
title_fullStr Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs
title_full_unstemmed Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs
title_short Pharmacological Safety in Pregnancy: A Systematic Review On the Use of Potentially Teratogenic Drugs
title_sort pharmacological safety in pregnancy a systematic review on the use of potentially teratogenic drugs
topic pharmacoepidemiology
pregnancy
drugs
teratogen
safety
systematic review
url https://www.pedpharma.ru/jour/article/view/1513
work_keys_str_mv AT olgavreshetko pharmacologicalsafetyinpregnancyasystematicreviewontheuseofpotentiallyteratogenicdrugs
AT konstantinalutsevich pharmacologicalsafetyinpregnancyasystematicreviewontheuseofpotentiallyteratogenicdrugs
AT irinaisanina pharmacologicalsafetyinpregnancyasystematicreviewontheuseofpotentiallyteratogenicdrugs